HomeIngredientStructural elucidation of three novel oligosaccharides from Kunlun Chrysanthemum flower tea and their bioactivities

Structural elucidation of three novel oligosaccharides from Kunlun Chrysanthemum flower tea and their bioactivities

February 3, 2022

Food Chem Toxicol. 2021 Mar;149:112032. doi: 10.1016/j.fct.2021.112032. Epub 2021 Jan 30.

ABSTRACT

Coreopsis tinctoria is commonly called Kunlun Chrysanthemum and a plateau plant with tremendous commercial value in functional tea and medicinal applications. In folk medicine, Kunlun Chrysanthemum flower is often used as an adjunctive therapy for diabetes and Alzheimer’s disease. To further explore the chemicals responsible for the health benefits of Kunlun Chrysanthemum flowers, three homogeneous oligosaccharides, CT70-1A, CT70-1B and CT70-2 were isolated, and their detailed structures were determined from chemical and spectral analyses. The three oligosaccharides were composed of glucose, mannose, galactose, and arabinose in different ratios. They showed dose-dependent α-amylase and α-glucosidase inhibitory effects. In addition, they showed NO production inhibitory activities in BV2 cells, with IC50 values of 0.23, 0.24 and 0.27 mM, respectively. Taken together, these results suggested that Kunlun Chrysanthemum oligosaccharides might ameliorate hyperglycemia and neuroinflammation, which could prevent the development of diseases such as type 2 diabetes and Alzheimer’s disease. This study provides chemical and bioactive perspectives that support the consumption of Kunlun Chrysanthemum flower tea for health benefits.

PMID:33529680 | DOI:10.1016/j.fct.2021.112032

Tags:

Related Posts

About The Author

Patrick Blanchard MD

Meet Dr. Blanchard Dr. Blanchard’s medical practice is an embodiment of Integrative health which brings conventional and complementary approaches together in a coordinated way. Conveniently located in sunny Florida and over the internet with ValiseMD’s secure HIPPA compliant telXmed servers. Since 1994, patients with a wide range of challenging medical problems have achieved optimum health using the best of natural medicine, judiciously combined with high-tech innovations. Breakthroughs are often achieved even after patients have consulted mainstream specialists and holistic practitioners. Dr. Blanchard is founder and CEO of ValiseMD, Inc. He is board certified in Family Medicine since 1994 and awarded Fellow of the American Academy of Family Physicians in 2001. He received the ‘Teacher of the Year’ award from the University of Kansas School of Medicine at completion of his residency in Family Medicine. He completed a fellowship at Wake Forest University in the field of vascular neurosonology. He holds a medical patent in the field of Gastroenterology. He holds an unrestricted license to practice medicine and surgery in Florida. He started his medical career as a Emergency Medical Technician, then as a Paramedic and later a Medical Doctor.